Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AbSolutions Med’s lead product, the REBUILD Bioabsorbable abdominal wall closure device, is designed to distribute suture tension over a large area of tissue during abdominal surgery closures. The goal is to reduce the risk of incisional hernia by supporting intrinsic tissue healing and eliminating long-term foreign bodies associated with mesh implants. The device has shown promising results in animal and early human studies and received FDA Breakthrough Device Designation in January 2024. A clinical trial began enrolling a broader patient population in March 2023, with primary completion expected September 2024.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on AbSolutions Med.